Exact Mass: 429.20860160000007
Exact Mass Matches: 429.20860160000007
Found 86 metabolites which its exact mass value is equals to given mass value 429.20860160000007,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Guan-fu base A
Guanfu base A is an antiarrhythmic alkaloid isolated from Aconitum coreanum and is a potent noncompetitive CYP2D6 inhibitor, with a Ki of 1.20 μM in human liver microsomes (HLMs) and a Ki of 0.37 μM for the human recombinant form (rCYP2D6). Guanfu base A is also a potent competitive inhibitor of CYP2D in monkey (Ki of 0.38 μM) and dog (Ki of 2.4 μM) microsomes[1]. Guanfu base A also inhibits HERG channel current[2]. Guanfu base A is an antiarrhythmic alkaloid isolated from Aconitum coreanum and is a potent noncompetitive CYP2D6 inhibitor, with a Ki of 1.20 μM in human liver microsomes (HLMs) and a Ki of 0.37 μM for the human recombinant form (rCYP2D6). Guanfu base A is also a potent competitive inhibitor of CYP2D in monkey (Ki of 0.38 μM) and dog (Ki of 2.4 μM) microsomes[1]. Guanfu base A also inhibits HERG channel current[2].
Hippuryl-histidyl-leucine
C21H27N5O5 (429.20120920000005)
Sarpogrelate
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist D006401 - Hematologic Agents > D005343 - Fibrinolytic Agents D050299 - Fibrin Modulating Agents D002317 - Cardiovascular Agents
2-amino-3-[[(6E,9E)-5-hydroxy-8-methoxy-5,9,13,14-tetramethyl-2-oxo-1-oxacyclotetradeca-6,9-dien-4-yl]sulfanyl]propanoic acid
C21H35NO6S (429.21849700000007)
(-)N-(12-Acetoxy)jasmonoyl-phenylalaninmethylester
acehytisine
Guanfu base A is an antiarrhythmic alkaloid isolated from Aconitum coreanum and is a potent noncompetitive CYP2D6 inhibitor, with a Ki of 1.20 μM in human liver microsomes (HLMs) and a Ki of 0.37 μM for the human recombinant form (rCYP2D6). Guanfu base A is also a potent competitive inhibitor of CYP2D in monkey (Ki of 0.38 μM) and dog (Ki of 2.4 μM) microsomes[1]. Guanfu base A also inhibits HERG channel current[2]. Guanfu base A is an antiarrhythmic alkaloid isolated from Aconitum coreanum and is a potent noncompetitive CYP2D6 inhibitor, with a Ki of 1.20 μM in human liver microsomes (HLMs) and a Ki of 0.37 μM for the human recombinant form (rCYP2D6). Guanfu base A is also a potent competitive inhibitor of CYP2D in monkey (Ki of 0.38 μM) and dog (Ki of 2.4 μM) microsomes[1]. Guanfu base A also inhibits HERG channel current[2].
C21H35NO6S_Cysteine, S-[(6E,9E)-5-hydroxy-8-methoxy-5,9,13,14-tetramethyl-2-oxooxacyclotetradeca-6,9-dien-4-yl]
C21H35NO6S (429.21849700000007)
2-amino-3-[[(6E,9E)-5-hydroxy-8-methoxy-5,9,13,14-tetramethyl-2-oxo-1-oxacyclotetradeca-6,9-dien-4-yl]sulfanyl]propanoic acid_major
C21H35NO6S (429.21849700000007)
Ala Gly Pro Trp
C21H27N5O5 (429.20120920000005)
Ala Gly Trp Pro
C21H27N5O5 (429.20120920000005)
Ala Pro Gly Trp
C21H27N5O5 (429.20120920000005)
Ala Pro Trp Gly
C21H27N5O5 (429.20120920000005)
Ala Trp Gly Pro
C21H27N5O5 (429.20120920000005)
Ala Trp Pro Gly
C21H27N5O5 (429.20120920000005)
Gly Ala Pro Trp
C21H27N5O5 (429.20120920000005)
Gly Ala Trp Pro
C21H27N5O5 (429.20120920000005)
Gly Pro Ala Trp
C21H27N5O5 (429.20120920000005)
Gly Pro Trp Ala
C21H27N5O5 (429.20120920000005)
Gly Trp Ala Pro
C21H27N5O5 (429.20120920000005)
Gly Trp Pro Ala
C21H27N5O5 (429.20120920000005)
Pro Ala Gly Trp
C21H27N5O5 (429.20120920000005)
Pro Ala Trp Gly
C21H27N5O5 (429.20120920000005)
Pro Gly Ala Trp
C21H27N5O5 (429.20120920000005)
Pro Gly Trp Ala
C21H27N5O5 (429.20120920000005)
Pro Trp Ala Gly
C21H27N5O5 (429.20120920000005)
Pro Trp Gly Ala
C21H27N5O5 (429.20120920000005)
Trp Ala Gly Pro
C21H27N5O5 (429.20120920000005)
Trp Ala Pro Gly
C21H27N5O5 (429.20120920000005)
Trp Gly Ala Pro
C21H27N5O5 (429.20120920000005)
Trp Gly Pro Ala
C21H27N5O5 (429.20120920000005)
Trp Pro Ala Gly
C21H27N5O5 (429.20120920000005)
Trp Pro Gly Ala
C21H27N5O5 (429.20120920000005)
2-hydroxyethyl 2-methylprop-2-enoate,2-methylidenehexanoate,methyl 2-methylprop-2-enoate,prop-2-enoic acid
C21H33O9- (429.21244680000007)
Thiourea, N-[2-(5,6-dimethyl-1H-benzimidazol-2-yl)ethyl]-N-(3-methylphenyl)-N-(3-pyridinylmethyl)- (9CI)
C25H27N5S (429.19870620000006)
3-{2-[4-(4-fluoro-2-hydroxybenzoyl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
C23H28FN3O4 (429.20637400000004)
Evobrutinib
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163774 - BTK-targeting Agent
7-[2(S)-[3(R)-Hydroxy-4-[3-(trifluoromethyl)phenyl]butyl]-5-oxopyrrolidin-1-yl]heptanoic acid
C22H30F3NO4 (429.21268160000005)
Sarpogrelate
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist D006401 - Hematologic Agents > D005343 - Fibrinolytic Agents D050299 - Fibrin Modulating Agents D002317 - Cardiovascular Agents
2-Amino-6-ethyl-4-(4-methoxyphenyl)-8-[(4-methoxyphenyl)methyl]-4,5-dihydropyrano[3,2-c]pyridine-3-carbonitrile
C26H27N3O3 (429.20523120000007)
1-[2-[[4,6-Bis(4-morpholinyl)-1,3,5-triazin-2-yl]oxy]ethyl]-3-phenylurea
C20H27N7O4 (429.21244220000005)
N-[1-methyl-2-[2-(4-phenyl-1-piperazinyl)ethyl]-5-benzimidazolyl]-2-furancarboxamide
4-[[[2-(1-Azepanyl)ethyl-(2-furanylmethyl)amino]-sulfanylidenemethyl]amino]benzoic acid ethyl ester
C23H31N3O3S (429.20860160000007)
2-[cyclohexyl-(2,4,6-trimethylphenyl)sulfonylamino]-N-(3-pyridinylmethyl)acetamide
C23H31N3O3S (429.20860160000007)
1-methyl-4-[2-oxo-2-(N-(phenylmethyl)anilino)ethyl]-5-pyrrolo[3,2-b]pyrrolecarboxylic acid propan-2-yl ester
C26H27N3O3 (429.20523120000007)
2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[[(3-methoxyanilino)-oxomethyl]amino]-2-oxanyl]-N-(4-pyrimidinylmethyl)acetamide
C21H27N5O5 (429.20120920000005)
2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[[(3-methoxyanilino)-oxomethyl]amino]-2-oxanyl]-N-(4-pyrimidinylmethyl)acetamide
C21H27N5O5 (429.20120920000005)
2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[[(3-methoxyanilino)-oxomethyl]amino]-2-oxanyl]-N-(4-pyrimidinylmethyl)acetamide
C21H27N5O5 (429.20120920000005)
2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[[(3-methoxyanilino)-oxomethyl]amino]-2-oxanyl]-N-(4-pyrimidinylmethyl)acetamide
C21H27N5O5 (429.20120920000005)
2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[[(3-methoxyanilino)-oxomethyl]amino]-2-oxanyl]-N-(4-pyrimidinylmethyl)acetamide
C21H27N5O5 (429.20120920000005)
2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[[(3-methoxyanilino)-oxomethyl]amino]-2-oxanyl]-N-(4-pyrimidinylmethyl)acetamide
C21H27N5O5 (429.20120920000005)
2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[[(3-methoxyanilino)-oxomethyl]amino]-2-oxanyl]-N-(4-pyrimidinylmethyl)acetamide
C21H27N5O5 (429.20120920000005)
2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[[(3-methoxyanilino)-oxomethyl]amino]-2-oxanyl]-N-(4-pyrimidinylmethyl)acetamide
C21H27N5O5 (429.20120920000005)
(3S,12Z)-14,14,21,21-tetramethyl-22-oxa-5,11,16-triazahexacyclo[13.11.0.03,11.05,9.017,26.018,23]hexacosa-1(15),8,12,17(26),18(23),19,24-heptaene-4,10-dione
C26H27N3O3 (429.20523120000007)
(3S,12Z)-14,14,21,21-tetramethyl-20-oxa-5,11,16-triazahexacyclo[13.11.0.03,11.05,9.017,26.019,24]hexacosa-1(15),8,12,17(26),18,22,24-heptaene-4,10-dione
C26H27N3O3 (429.20523120000007)
2-amino-3-[[(6Z,9Z)-5-hydroxy-8-methoxy-5,9,13,14-tetramethyl-2-oxo-1-oxacyclotetradeca-6,9-dien-4-yl]sulfanyl]propanoic acid
C21H35NO6S (429.21849700000007)
BML-280
BML-280 (VU0285655-1) is a potent and selective phospholipase D2 (PLD2) inhibitor. BML-280 has the ability to prevent caspase-3 cleavage and reduction in cell viability induced by high glucose. BML-280 can be used for rheumatoid arthritis research[1][2].